ROP is the leading cause of blindess in infants in the world. In India one out of three babies born less than 2000gm develops the disease and 10 per cent of the babies will turn blind at the age of two months if not treated on time.
Bengaluru-based Medical Devices Company Forus Health Private Limited has recently announced the launch of its ROP (Retinopathy of Prematurity) imaging platform - 3nethra NEO.
Founded in 2010, Forus Health has a mission to eradicate preventable blindness using technology and has successfully deployed thousands of its flagship adult retinal imaging device – 3nethra classic in 25 countries.
Commenting on the same, Dr. Shyam Vasudeva Rao, Founder and Director, Forus Health said, “3nethra neo is the most affordable ROP imaging device with an integrated telemedicine platform that helps in remote diagnosis. The device costs one fourth of its nearest competitor. We have 4 design patents for this product. This not only protects our design but also makes it far superior.”
Reportedly, over 3.5 million babies are born premature in India every year and there are less than 100 ROP specialists nationwide to screen and treat this condition.
“3nethra NEO is a result of our continued efforts in building affordable and state of the art imaging solutions for eye care.Our collaboration with Narayayana Nethralaya has helped us realise our dream of effectively building products and solutions to prevent ROP blindness in pre-term babies,” informed K Chandrasekhar, Founder & CEO of Forus Health.
Interestingly, the startup has collaborated with Narayana Nethralaya for development and clinical validation of 3nethra neo.
The Bengaluru-based company has been managed by highly experienced professionals with a passion to build world class products and solutions that touches lives of millions of people.Forus Health continues to innovate products in the ophthalmology space and is backed by marquee investors - Accel Partners, IDG Ventures and Asian Health Fund.